Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy

Survival: 13.1 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Italy
City/State/Province: Napoli
Hospital: Istituto Nazionale Tumori Fondazione Pascale
Journal: Link
Date: 9/2013

This phase 2 study involved metastatic melanoma patients who were divided into separate groups based on the specific genetic mutation of their cancer. Group A consisted of 76 patients with the BRAF V600E mutation. Group B consisted of 16 patients with the BRAF V600K mutation. The median patient age for the total group of patients was 55.5 years and 53% of all patients were male.

Patients in both groups received biologic therapy with dabrafenib, which is a BRAF kinase inhibitor that interferes with cancer cell growth.

The most severe toxicities in the total group of patients were of grade 4, but were not specified. Grade 3 arthralgia (joint pain), headache, anemia, and cutaneous squamous cell carcinoma were reported.

The median overall survival rates for groups A and B were 13.1 and 12.9 months, respectively.

This study was supported by GlaxoSmithKline.

Correspondence: Dr. Paolo A. Ascierto; email:

E-mail to a Friend Email Physician More Information